AstraZeneca: Phase 2 endpoint not met in COPD
Initial results from the trial show that the drug, administered by injection, reduced exacerbations of COPD-related symptoms by only 17% over a full year, a level deemed statistically insignificant.
The laboratory does, however, highlight data deemed 'encouraging' in patients with a blood eosinophil count greater than or equal to 150 cells/µL, a sub-category which accounts for 65% of COPD patients.
In this patient population, the reduction in moderate or severe exacerbations reached 37%, a result that can be considered significant this time.
Tezspire, developed in collaboration with Amgen, is a human monoclonal antibody that inhibits a key cytokine responsible for the persistence of allergic-type respiratory inflammation.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction